Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-GEMD vs P-Gemox in Untreated ENKTL
NCT06953739Phase 3Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 3, randomised, open-label trial of mitoxantrone in Extranodal NK/T-cell lymphoma (ENKTL) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Complete Response Rate at 5.5 years. Planned start May 2025; status: not yet recruiting.
02
Drugs
mitoxantrone
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT06953739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953739.